2026-09-11 · 💊 FDA / Trial
Why is GTBP stock up today?
GT Biopharma Inc. Common Stock · GTBP · updated 2026-09-11
PRICE$8.61
CHANGE+39.3%
VOLUME0.5M
6-DAY
In plain English
The only news (“A Third Cancer Drug Just Entered the Clinic at an Under-$2…”) is stale (101d old) — too old to explain today's move. Likely momentum, not news.
What it means for you
Finished the day strong — closed near its highs on heavy volume. Risk level: moderate.
Source: Benzinga: A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company (2026-06-02)
About GT Biopharma Inc. Common Stock
Market cap$11.2M
ExchangeXNAS
Employees1
HQSAN FRANCISCO, CA
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers i
Get moves like this before the bell
Free daily email — the biggest movers, explained. No spam.
Not financial advice. Educational only. AI-assisted summary — verify against the linked source. Data may be delayed.